Although MEDI9197 increased tumor CD8+ and PD-L1+ cells and induced type 1 and type 2 interferon and Th1 responses, MEDI9197-associated adverse events (AE) frequently occurred, resulting in dose-limiting toxicity (DLT) with cytokine release syndrome and, even more serious, in one patient (grade 5) resulted in two cycles of MEDI919 hemorrhagic shock associated with DLT after the rupturing of liver metastasis. Here, CD8A is linked to neoplasm.